参考文献/References:
[1] Daniel LB,Maisel AS.Natriuretic peptides [J]. J Am Coll Cardiol,2007,50:2357-2368.
[2] Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure[J]. JACC Heart Fail,2014,2:663-670.
[3] Macheret F, Heublein D, Costello-Boerrigter LC, et al. Human hypertension is characterized by a lack of activation of the anti-hypertensive cardiac hormones ANP and BNP[J]. J Am Coll Cardiol,2011,57:1386-1395.
[4] Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels[J]. Circulation,2004,109:594-600.
[5] McKie PM, Cataliotti A, Sangaralingham SJ, et al. Predictive utility of atrial, N-terminal pro-atrial, and N-terminal pro-B-type natriuretic peptides for mortality and cardiovascular events in the general community: a 9-year follow-up study[J]. Mayo Clin Proc,2011,86:1154-1160.
[6] von Lueder TG, Krum H.RASS inhibitors and cardiovascular protection in large scale trials[J].Cardiovasc Drugs Ther,2013,27:171-179.
[7] Bertrand M, Akkerhuis KM, Brugts JJ,et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients[J]. Eur Heart J,2013,33:2088-2097.
[8] Feng L, Karpinski PH, Sutton P, et al. LCZ696:a dual-acting sodium supramolecular complex[J]. Tetrahedron Lett,2012,53:275-276.
[9] Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor(ARNi)[J]. J Clin Pharmacol,2010,50:401-414.
[10] Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events(OVERTURE)[J]. Circulation,2002,106:920-926.
[11] Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril(OCTAVE)trial[J].Am J Hypertens,2004,17(2):103-111.
[12] Ruilope LM, Dukat A, Böhm M, et al.Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin Ⅱ receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study[J]. Lancet,2010,375:1255-1266.
[13] Safar ME. Systolic blood pressure, pulse pressure and arterial stiffness as cardiovascular risk factors[J]. Curr Opin Nephrol Hypertens,2001,10:257-261.
[14] Haider AW, Larson MG, Franklin SS, et al. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study[J]. Ann Intern Med,2003,138:10-16.
[15] Kario K, Sun N, Chiang FT.Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension[J]. Hypertension,2014,63:698-705.
[16] Kario K, Pickering TG, Umeda Y, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study[J].Circulation,2003,107(10):1401-1406.
[17] Kario K. Proposal of a new strategy for ambulatory blood pressure profile-based management of resistant hypertension in the era of renal denervation[J].Hypertens Res,2013,36:478-484.
[18] Lund LH, Benson L, Dahlström U,et al.Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction[J]. JAMA,2014,312(19):2008-2018.
[19] Shah RV, Desai RS, Givertz MM. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalizations in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis[J]. J Card Fail,2010,16:260-267.
[20] Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial[J].Lancet,2012,380:1387-1395.
[21] Jhund PS, Claggett B, Packer M,et al. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction:an analysis of the PARAMOUNT trial[J].Eur J Heart Fail,2014,16:671-677.
[22] Jhund PS,Claqqett BL,Voors AA,et al. Elevation in high sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696[J].Circ Heart Fail, 2014,7(6):953-959.
[23] McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med,2014,371:993-1004.
[24] McMurray JJ, Packer M, Desai AS, et al. Baseline characteristics and treatment of patients in Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure trial(PARADIGM-HF)[J].Eur J Heart Fail,2014,16:817-825.
[25] Packer M, McMurray JJ, Desai AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure[J].Circulation,2015,131(1):54-61.
[26] McMurray J, Packer M, Desai A, et al. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure[J]. Eur Heart J,2015,36(7):434-439.
[27] Bodey F, Hopper I, Krum H. Neprilysin inhibitors preserve renal function in heart failure[J]. Int J Cardiol,2015,179:329-330.
[28] von Lueder TG, Wang BH, Kompa AR, et al. The angiotensin-receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy[J]. Circ Heart Fail,2015,8(1):71-78.
[29] Vodovar N, Paquet C, Mebazaa A, et al. Neprilysin, cardiovascular, and Alzheimer's diseases: the therapeutic split?[J]. Eur Heart J,2015,36:902-905.
[30] Hajjar I, Rodgers K. Do angiotensin receptor blockers prevent Alzheimer's disease?[J].Curr Opin Cardiol,2013,28:417-425.